Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Uniqure N.V. (QURE)

40.87   -0.82 (-1.97%) 08-14 16:00
Open: 41.37 Pre. Close: 41.69
High: 41.37 Low: 40.15
Volume: 176,827 Market Cap: 1,817M
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 41.418 - 41.637 41.637 - 41.822
Low: 39.636 - 39.882 39.882 - 40.091
Close: 40.463 - 40.884 40.884 - 41.242

Technical analysis

as of: 2020-08-14 4:33:42 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 51.00     One year: 56.18
Support: Support1: 36.49    Support2: 30.36
Resistance: Resistance1: 43.66    Resistance2: 48.10
Pivot: 41.02
Moving Average: MA(5): 41.22     MA(20): 41.23
MA(100): 53.16     MA(250): 54.34
MACD: MACD(12,26): -1.81     Signal(9): -2.40
Stochastic oscillator: %K(14,3): 70.63     %D(3): 68.65
RSI: RSI(14): 39.65
52-week: High: 76.69  Low: 36.20  Change(%): -28.1
Average Vol(K): 3-Month: 59648  10-Days: 28279

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
QURE has closed above bottom band by 47.0%. Bollinger Bands are 62.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to QURE's normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 14 Aug 2020
Aug 14, 2020 - Foresite Capital Management IV, LLC Buys Keros Therapeutics Inc, Fulcrum Therapeutics Inc, Kura Oncology Inc, Sells Insmed Inc, MyoKardia Inc, Cytokinetics Inc - GuruFocus.com

Fri, 14 Aug 2020
Estimating Price Trends For uniQure N.V. (NASDAQ: QURE) - The Comet Reports

Fri, 31 Jul 2020
Uniqure (NASDAQ:QURE) Posts Earnings Results, Misses Expectations By $0.31 EPS - MarketBeat

Fri, 31 Jul 2020
Mizuho Securities Stick to Their Hold Rating for uniQure N.V. - Investing.com

Thu, 30 Jul 2020
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Thu, 30 Jul 2020
A Quick Investment Idea On uniQure - Seeking Alpha

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 44
Shares Float (M) 34
% Held by Insiders 7.80
% Held by Institutions 95.93
Shares Short (K) 3,710
Shares Short P. Month (K) 4,500

Stock Financials

EPS -2.990
EPS Est This Year -2.970
EPS Est Next Year -2.650
Book Value (p.s.) 6.670
Profit Margin
Operating Margin -2049.91
Return on Assets (ttm) -23.4
Return on Equity (ttm) -55.0
Qtrly Rev. Growth -90.8
Gross Profit (p.s.) -1.974
Sales Per Share 0.141
EBITDA (p.s.) -2.737
Qtrly Earnings Growth
Operating Cash Flow (M) -105
Levered Free Cash Flow (M) -67

Stock Valuations

PE Ratio -13.67
PEG Ratio
Price to Book value 6.13
Price to Sales 289.69
Price to Cash Flow -17.21

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.